Vir Biotechnology, Inc. (NYSE:VIR)
Industry: Consumer Goods

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.

Current Quote*
Last: $28.690
Change: -0.310
Book: $Unk
Volume: 224,358

As Of: 04/03 13:00 ET
*Quotes delayed by 20min.

Graphs for VIR


3 Month Graph


6 Month Graph


1 Year Graph